TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11695214

Group type: EXPERIMENTAL
Intervention: Colgate Total Plus Whitening Toothpaste
Number of subjects: 123

Group type: COMPARATOR
Intervention: Crest Multi‐Care Advanced Cleaning Toothpaste
Number of subjects: 123

Group type: COMPARATOR
Intervention: Colgate Winterfresh Gel Fluoride Toothpaste
Number of subjects: 123
Study: 9585725

Group type: EXPERIMENTAL
Intervention: Tomoxetine (76 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tomoxetine
Number of subjects: 22
Study: 7814794

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2672610

Group type: EXPERIMENTAL
Intervention: Migen (M)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pharmalgen (P)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 791107

Group type: EXPERIMENTAL
Intervention: Doxycycline (2 mg/kg at the beginning, at 12 h, and once daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride (administered at 6-h intervals)
Number of subjects: 51
Study: 30173574

Group type: EXPERIMENTAL
Intervention: Early driving (2-3 weeks post birth)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Late driving (5-6 weeks post birth)
Number of subjects: 66
Study: 31577396

Group type: EXPERIMENTAL
Intervention: Moderate therapeutic hypothermia (33°C during the first 24 hours)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Targeted normothermia (37°C)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Moderate therapeutic hypothermia (33°C)
Number of subjects: 581
Study: 28349044

Group type: EXPERIMENTAL
Intervention: VPZ-based treatment (VPZ 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days)
Number of subjects: 141

Group type: COMPARATOR
Intervention: PPI-based treatment (rabeprazole 20 mg or lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: VPZ-based treatment
Number of subjects: 141

Group type: COMPARATOR
Intervention: PPI-based treatment
Number of subjects: 141
Study: 25253443

Group type: EXPERIMENTAL
Intervention: Standard information plus 'The Gist' leaflet (Gist + Facts, n = 2,236)
Number of subjects: 4452

Group type: COMPARATOR
Intervention: Standard information ('The Facts', n = 2,216)
Number of subjects: 4452

Group type: EXPERIMENTAL
Intervention: Both groups (Gist + Facts and Facts)
Number of subjects: 4452
Study: 23725941

Group type: EXPERIMENTAL
Intervention: High-fidelity colonoscopy model (AccuTouch CS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-fidelity colonoscopy model
Number of subjects: 32
Study: 21536441

Group type: EXPERIMENTAL
Intervention: Unilateral hip isokinetic exercises of the dominant leg for two weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 18053998

Group type: EXPERIMENTAL
Intervention: Synthetic conjugated estrogens B (0.3 mg/d)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 17212913

Group type: EXPERIMENTAL
Intervention: Conservative treatment (medications, physical therapy, epidural steroid injections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment (laminectomy)
Number of subjects: 0
Study: 14975774

Group type: EXPERIMENTAL
Intervention: Cue condition (glove puppets and post boxes)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No cue condition
Number of subjects: 96
Study: 11349266

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), 1 g twice daily intravenously followed by 1.5 g twice daily orally
Number of subjects: 565

Group type: COMPARATOR
Intervention: Azathioprine (AZA), 1.0 to 2.0 mg/kg/d intravenously followed by oral administration
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) and Azathioprine (AZA)
Number of subjects: 565
Study: 9000705

Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional diabetes therapy
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 1441
Study: 8480551

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) with salbutamol (S)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DNCG) with salbutamol (S)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo with salbutamol (S)
Number of subjects: 36
Study: 3435159

Group type: EXPERIMENTAL
Intervention: Human normal immunoglobulin (50 mg/kg) administered weekly via intramuscular injection
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-treated group (control)
Number of subjects: 120
Study: 29564942

Group type: EXPERIMENTAL
Intervention: Percutaneous closure of patent foramen ovale (PFO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 0
Study: 27033672

Group type: EXPERIMENTAL
Intervention: gemcitabine plus intensity-modulated radiotherapy (gem-IMRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: gemcitabine plus stereotactic body radiotherapy (gem-SBRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: gemcitabine alone (gem-alone)
Number of subjects: 0
Study: 25558162

Group type: EXPERIMENTAL
Intervention: Varunadi Ghritha, 5gms twice daily for one year
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 78
Study: 23548529

Group type: EXPERIMENTAL
Intervention: Ecallantide 30 mg subcutaneously
Number of subjects: 98
Study: 20038852

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (100,000-200,000 IU)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 79
Study: 18538051

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg kg(‐1) loading dose followed by 0.2 microg kg(‐1) h(‐1))
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Midazolam/Fentanyl (0.05 mg kg(‐1) midazolam and 1 microg kg(‐1) fentanyl)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Midazolam/Fentanyl
Number of subjects: 49
Study: 16905079

Group type: EXPERIMENTAL
Intervention: 50% xenon and 1.5% sevoflurane (X50-S1.5)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 70% xenon and 1.5% sevoflurane (X70-S1.5)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide and 1.5% sevoflurane (G70-S1.5)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2.8% sevoflurane (S2.8)
Number of subjects: 32
Study: 14603706

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study: 10676716

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Antiplatelet treatment
Number of subjects: 21
Study: 10169534

Group type: EXPERIMENTAL
Intervention: Alternate survey form
Number of subjects: 4056

Group type: COMPARATOR
Intervention: Standard survey form
Number of subjects: 4056

Group type: EXPERIMENTAL
Intervention: Alternate survey form Overall Value
Number of subjects: 4056
Study: 8154263

Group type: EXPERIMENTAL
Intervention: Lacrozym
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tears Naturale
Number of subjects: 0
Study: 3014408

Group type: EXPERIMENTAL
Intervention: Water-soluble contrast media
Number of subjects: 106

Group type: COMPARATOR
Intervention: Oil-soluble contrast media
Number of subjects: 106
Study: 30332353

Group type: EXPERIMENTAL
Intervention: Parent and Child Enhancement (PACE) program
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study: 27507005

Group type: EXPERIMENTAL
Intervention: Glucose drink (0.75 g/kg body weight)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Whey protein drink (0.75 g/kg body weight)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sucralose (control)
Number of subjects: 36
Study: 24887106

Group type: EXPERIMENTAL
Intervention: Exercise group (N = 8)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sedentary group (N = 6)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 22265809

Group type: EXPERIMENTAL
Intervention: Stent placement as a bridge to surgery (Group B)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Emergency surgical resection (Group A)
Number of subjects: 86
Study: 20042442

Group type: COMPARATOR
Intervention: Forced Air (FA) warming
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Resistive-Polymer (RP) warming
Number of subjects: 80
Study: 18341431

Group type: EXPERIMENTAL
Intervention: Topical latanoprost (LA) administered once-daily for 3 months after switching from beta-blockers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical beta-blockers (carteolol hydrochloride, nipradilol, betaxolol hydrochloride) administered twice-daily for 3 months before switching to LA
Number of subjects: 60
Study: 15980931

Group type: EXPERIMENTAL
Intervention: Enriched drink (n=20)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 33
Study: 12432966

Group type: EXPERIMENTAL
Intervention: Extended-release Adderall 20 mg (formulation A)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Extended-release Adderall 20 mg (formulation B)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Extended-release Adderall 20 mg (formulation C)
Number of subjects: 41

Group type: COMPARATOR
Intervention: SLI381 30 mg (intact capsule)
Number of subjects: 41

Group type: COMPARATOR
Intervention: SLI381 30 mg (sprinkled in applesauce)
Number of subjects: 41
Study: 9803648

Group type: EXPERIMENTAL
Intervention: 16-week exercise group (supervised aerobic sessions, 3 times per week)
Number of subjects: 146

Group type: COMPARATOR
Intervention: 16-week health education group (instructed to exercise aerobically on their own, 3 times per week)
Number of subjects: 146
Study: 8582462

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene napsylate 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene napsylate 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3407612

Group type: EXPERIMENTAL
Intervention: 30 mg Zn/d supplementation for 28 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 53
Study: 29325446

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28246046

Group type: EXPERIMENTAL
Intervention: Minimally invasive approach (group A)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Conventional approach (group B)
Number of subjects: 157
Study: 26169008

Group type: EXPERIMENTAL
Intervention: PolyScope (multimodular flexible ureteroscope)
Number of subjects: 360

Group type: COMPARATOR
Intervention: URF P-5 (conventional flexible ureteroscope)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: PolyScope
Number of subjects: 360

Group type: COMPARATOR
Intervention: URF P-5
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: PolyScope and URF P-5
Number of subjects: 360
Study: 23315607

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment using the Montreal Cognitive Assessment (MoCA) at baseline during inpatient stay.
Number of subjects: 260
Study: 21821810

Group type: COMPARATOR
Intervention: Pearl millet‐soybean meal diet (PM)
Number of subjects: 160

Group type: COMPARATOR
Intervention: CTL + exogenous enzymes (CE)
Number of subjects: 160

Group type: COMPARATOR
Intervention: PM + exogenous enzymes (PE)
Number of subjects: 160
Study: 19247545

Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Active placebo device
Number of subjects: 119
Study: 17367216

Group type: EXPERIMENTAL
Intervention: Halo cast (nonsurgical management)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 40
Study: 15148063

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 120
Study: 11601116

Group type: EXPERIMENTAL
Intervention: Aquatic therapy (pool exercise therapy)
Number of subjects: 0
Study: 9013436

Group type: EXPERIMENTAL
Intervention: High heart rate intensity exercise (HI, N = 8) - exercised at a mean heart rate of 163 bpm for 40 to 45 minutes approximately four times weekly.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low heart rate intensity exercise (LI, N = 7) - exercised at a mean heart rate of 132 bpm for 40 to 45 minutes approximately four times weekly.
Number of subjects: 15
Study: 8174448

Group type: EXPERIMENTAL
Intervention: Diabetic patients with neuropathy
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Diabetic patients with a history of foot ulceration
Number of subjects: 187

Group type: COMPARATOR
Intervention: Non‐neuropathic patients
Number of subjects: 187

Group type: COMPARATOR
Intervention: Nondiabetic age‐matched control subjects
Number of subjects: 187
Study: 3928919

Group type: EXPERIMENTAL
Intervention: BCAA (valine, leucine, isoleucine) at 0.5 g/kg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BCAA (valine, leucine, isoleucine) at 1.0 g/kg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg of essential and nonessential AA solution with a prevalence of BCAA
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard diet (Control group D)
Number of subjects: 36
Study: 30721181

Group type: EXPERIMENTAL
Intervention: Lysobact
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 102
Study: 27567493

Group type: EXPERIMENTAL
Intervention: IVACFLU-S 15μg hemagglutinin of each of the three strains in 0.5mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25330508

Group type: EXPERIMENTAL
Intervention: Propensity score techniques
Number of subjects: 0
Study: 23083787

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily (titrated to 50 mg)
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1658
Study: 19903864

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment (4 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: NTG-induced vasodilation
Number of subjects: 39
Study: 18817955

Group type: EXPERIMENTAL
Intervention: Naftopidil 75 mg after dinner for 6 weeks
Number of subjects: 122
Study: 17397979

Group type: EXPERIMENTAL
Intervention: Rightward optokinetic stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leftward optokinetic stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline (no stimulation)
Number of subjects: 0
Study: 15018436

Group type: EXPERIMENTAL
Intervention: 10,000 IU hCG
Number of subjects: 0

Group type: COMPARATOR
Intervention: None (control)
Number of subjects: 0
Study: 11429021

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1 g tid) for 12 weeks after intravenous ganciclovir (5 mg/kg/day for 5-10 days)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Oral acyclovir (400 mg tid) for 12 weeks after intravenous ganciclovir (5 mg/kg/day for 5-10 days)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 155

Group type: COMPARATOR
Intervention: Oral acyclovir
Number of subjects: 155
Study: 9261911

Group type: EXPERIMENTAL
Intervention: Two-stage procedure for adjusting regression effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of covariance model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed correlation structure model
Number of subjects: 0
Study: 8262130

Group type: EXPERIMENTAL
Intervention: Leuprolide plus flutamide (250 mg p.o. t.i.d.)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Leuprolide plus placebo
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Leuprolide plus flutamide (in patients with minimal disease and good performance status)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Leuprolide plus placebo (in patients with minimal disease and good performance status)
Number of subjects: 603
Study: 4023977

Group type: EXPERIMENTAL
Intervention: Inhaled lignocaine
Number of subjects: 10
Study: 31948455

Group type: EXPERIMENTAL
Intervention: Switching from teriparatide to alendronate (switch group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Continuous alendronate (ALD group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 48
Study: 30742829

Group type: EXPERIMENTAL
Intervention: Stress induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study: 28882233

Group type: EXPERIMENTAL
Intervention: Nighttime central apneas (CA)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Daytime central apneas (CA)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: 24-hour central apneas (CA)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Nighttime central apnea index (CAI)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Daytime central apnea index (CAI)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: 24-hour central apnea index (CAI)
Number of subjects: 525
Study: 24906665

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis for children with dilating VUR
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment or placebo
Number of subjects: 0
Study: 23496855

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 422

Group type: COMPARATOR
Intervention: Control
Number of subjects: 422
Study: 19883384

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) - Lindynette® and Cilest®
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-OC (control)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 19
Study: 19281738

Group type: EXPERIMENTAL
Intervention: Intermittent intravenous calcitriol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intermittent oral calcitriol
Number of subjects: 6
Study: 17002607

Group type: EXPERIMENTAL
Intervention: HE2000 (50 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HE2000 (50 mg or 100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15575824

Group type: COMPARATOR
Intervention: Orbital floor methylprednisolone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sub-Tenon triamcinolone
Number of subjects: 60
Study: 10778871

Group type: EXPERIMENTAL
Intervention: Stanol esters added to the test meal
Number of subjects: 11
Study: 9241012

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 238

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 238
Study: 7871057

Group type: EXPERIMENTAL
Intervention: Flumazenil pretreatment with diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam (BZ) without flumazenil pretreatment
Number of subjects: 0
Study: 3952023

Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 116

Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 116
Study: 31102719

Group type: EXPERIMENTAL
Intervention: VCTE
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: FibroMeter
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: FibroMeterVCTE
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: FIB4-FMVCTE algorithm
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: VCTE-FMVCTE algorithm
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: FIB4-FMVCTE and VCTE-FMVCTE algorithms
Number of subjects: 938
Study: 28970290

Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Hot Snare Polypectomy (HSP)
Number of subjects: 538
Study: 26918924

Group type: EXPERIMENTAL
Intervention: Trèswhite Ortho (TWO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trèswhite Supreme (TWS)
Number of subjects: 40
Study: 24757668

Group type: EXPERIMENTAL
Intervention: verum iTBS (intermittent theta burst stimulation)
Number of subjects: 44

Group type: COMPARATOR
Intervention: sham iTBS
Number of subjects: 44

Group type: COMPARATOR
Intervention: healthy controls (HC)
Number of subjects: 44
Study: 23007487

Group type: EXPERIMENTAL
Intervention: Full‐leg length compressive garment (76% Meryl Elastane, 24% Lycra)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Similar‐looking noncompressive placebo garment (92% Polyamide, 8% Lycra)
Number of subjects: 22
Study: 20718734

Group type: EXPERIMENTAL
Intervention: Haem arginate (HA) infusion
Number of subjects: 15
Study: 18456237

Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (17OHPC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 16446690

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) supplementation (3,600 mg x day‐1 for 14 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11926348

Group type: EXPERIMENTAL
Intervention: HRT (17‐beta‐oestradiol, norethisterone acetate, TTS, Estracomb Novartis)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no hormonal therapy)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 76
Study: 9666905

Group type: EXPERIMENTAL
Intervention: Psychophysical measurements for visual acuity (VA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychophysical measurements for contrast sensitivity (CS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychophysical measurements for colour vision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual acuity (VA) and colour vision tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening tests for advanced levels of background DR
Number of subjects: 0
Study: 7700657

Group type: EXPERIMENTAL
Intervention: Outpatient exercise program incorporating interesting, purposeful activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple home program of head movements
Number of subjects: 0